



## Rani Therapeutics to Participate in August Investor Conferences

August 4, 2023

SAN JOSE, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in three upcoming investor conferences in August 2023. These conferences include:

### **BTIG Virtual Biotechnology Conference**

Date: Monday, August 7<sup>th</sup> at 2:00pm E.T.

Format: Virtual Presentation and 1x1 Investor Meetings

Presenter: Chief Executive Officer, Talat Imran

### **Wedbush PacGrow Healthcare Conference**

Date: Tuesday, August 8, 2023 in New York, NY

Format: 1x1 Investor Meetings

### **Canaccord Genuity Annual Growth Conference**

Date: Thursday, August 10, 2023 at 1:00pm E.T. in Boston, MA

Format: Fireside Chat and 1x1 Investor Meetings

Presenter: Chief Executive Officer, Talat Imran

Interested parties can access the live webcasts for these conferences (if available) from the Investor Relations section of the company's website at [www.ranitherapeutics.com](http://www.ranitherapeutics.com). The webcast replays will be available after the conclusion of the respective presentations.

### **About Rani Therapeutics**

Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani is progressing two RaniPill® capsules, the RaniPill®GO and the RaniPill®HC. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit [ranitherapeutics.com](http://ranitherapeutics.com).

### **Investor Contact:**

[investors@ranitherapeutics.com](mailto:investors@ranitherapeutics.com)

### **Media Contact:**

[media@ranitherapeutics.com](mailto:media@ranitherapeutics.com)